Pepper Hamilton partner Barry Boise recently spoke during Pepper’s Life Sciences Speaker Series and provided an overview of lessons learned from recent enforcement against companies that have run afoul of regulations in marketing pharmaceuticals.
In this podcast, Barry summarizes his key points from the event, including addressing the pitfalls companies may encounter when sharing data with investors, and the risks of engaging in off label interactions with health care professionals.
If you are interested in reading more about the latest legal developments in the life sciences industry, email firstname.lastname@example.org to subscribe to Pepper’s Life Sciences Updates.
(Running Time: 12:28)
TrackBack URL for this entry:
Listed below are links to weblogs that reference Lessons for Life Science Companies Developing or Marketing Medicines or Medical Devices: